European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-18

Development of a Novel Treatment for Clostridium Difficile

Cel

"We wish to exploit the need for effective treatment for nosocomial diarrhoea especially that caused by Clostridium difficile

disease (CDD). Patients treated with broad spectrum antibiotics are at greatest risk of CDD diarrhoea and many of those

affected are hospitalised elderly patients with serious underlying illnesses. Antibiotics can cause disruption of the normal

intestinal flora, an important part of the immune system, leading to an overgrowth of CDD. Currently, some 2350 patients

suffering from chronic CDD in a number of countries have been treated by faecal bacteriotherapy (FB), using samples

collected from donors. Although this procedure is reported, in a number of small studies, to be around 90% effective, it is

hazardous, in that infection from the donor could be transmitted to the patient and it involves delivery of faecal samples into

the duodenum via a nasal probe.

We propose to treat CDD using a modified FB to restore the patient’s original intestinal flora (employing samples collected

from the patients themselves prior to their treatment) We will produce novel enteric-coated capsules, containing processed

freeze dried colonic flora that can be swallowed by a patient to restore their intestinal flora and immunise them against

further infection by CDD. RFID tags will be employed to associate capsules with the relevant patient and assist with sample

inventory.

3 SMEs in 3 EU states and 5 distinguished research providers along with 1 OTHER SME in the coordination role will collaborate to provide the necessary technology to the project. The coordinator has previously coordinated an EU proposal and acted as a participant in projects over several

Frameworks. The outcome will be a non-antibiotic medicament to treat and prevent CDD The consortium plan to patent the

IPR from the project, exploit and disseminate the technology worldwide and carry out animal and hospital clinical studies.

There are no gender issues related to the proposal but animal and human studies will require ethical approval."

Zaproszenie do składania wniosków

FP7-SME-2011
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

BSG-SME - Research for SMEs

Koordynator

PNO CONSULTANTS LIMITED
Wkład UE
€ 19 200,00
Adres
EARL ROAD 1 THE COURTYARD
SK8 6GN Cheadle Hulme
Zjednoczone Królestwo

Zobacz na mapie

Region
North West (England) Cheshire Cheshire East
Kontakt administracyjny
James Craven (Mr.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (8)